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Abstract 19 
Objectives: 20 
Vascular stiffness (VS) and calcification (VC) are surrogate markers of vascular health 21 
associated with cardiovascular events.  Vitamin K-dependent proteins (VKDP) are 22 
associated with VS and VC and require vitamin K for activity. We conducted a 23 
systematic review and meta-analysis of: (i) the effect of vitamin K supplementation on 24 
VS and VC, and (ii) association of inactive VKDP levels with incident cardiovascular 25 
disease and mortality. 26 
Methods 27 
Two authors searched Medline and Embase databases, Cochrane and ISRCTN 28 
registries for studies of vitamin K clinical trials which measured effects on VC, VS or 29 
VKDP, and longitudinal studies assessing effect of VKDP on incident CVD or mortality.  30 
Random effects meta-analyses were performed.   31 
Results 32 
Thirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10,726) met 33 
pre-specified inclusion criteria.  Vitamin K supplementation was associated with 34 
significant reduction in VC (-9.1% [95%CI -17.7; -0.5]; p=0.04) and VKDP 35 
(desphospho-uncarboxylated Matrix Gla Protein; -44.7% [-65.1; -24.3], p<0.0001) and 36 
uncarboxylated osteocalcin; -12.0% [-16.7; -7.2], p<0.0001) compared to control, with 37 
a non-significant improvement in VS.  In longitudinal studies with median follow-up 7.8 38 
(IQR 4.9-11.3) years, VKDP levels were associated with a combined endpoint of CVD 39 
or mortality (HR 0.45 [0.07 – 0.83], p=0.02).   40 
Conclusions: 41 
Supplementation with vitamin K significantly reduced VC, but not VS, compared to 42 
control. The conclusions drawn are limited by small numbers of studies with 43 
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substantial heterogeneity.  VKDP was associated with combined endpoint of CVD or 44 
mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, 45 
VS and long term cardiovascular health are warranted. 46 
 47 
Key questions 48 
What is already known about this subject? 49 
Vitamin K is essential for the activation of proteins that help maintain vascular health, 50 
including preventing vascular calcification and stiffness.  Vascular stiffness and 51 
calcification are associated with cardiovascular risk and may be exacerbated in 52 
subclinical vitamin K deficiency.  Vitamin K supplementation may improve markers of 53 
vascular health and long term cardiovascular risk. 54 
What does this study add? 55 
The existing clinical trial data describing the effect of vitamin K supplementation on 56 
vascular health and serum markers of vitamin K deficiency is summarised.  The 57 
findings are encouraging and justify ongoing study of vitamin K supplementation to 58 
improve cardiovascular risk. 59 
How might this impact on clinical practice? 60 
Assessment of vitamin K status and offering supplementation has the potential to be 61 
a cheap and safe intervention to improve vascular health and cardiovascular risk.  62 
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Introduction 63 
Older patients, and those with diabetes and chronic kidney disease (CKD) are at 64 
substantially increased risk of cardiovascular disease (CVD).  Independent of 65 
traditional cardiovascular risk factors, increased vascular stiffness (VS) is associated 66 
with future cardiovascular events[1] and often associated with presence of vascular 67 
calcification (VC).  There are currently no pharmacological means to improve VS and 68 
VC; a growing body of evidence supports beneficial effects of vitamin K on 69 
cardiovascular and bone health and may offer a cheap and safe therapeutic 70 
intervention. 71 
Vitamin K is a fat-soluble vitamin that is predominantly found in the form of 72 
phylloquinone (vitamin K1) in the western diet, from green, leafy vegetables (including 73 
kale, broccoli and spinach), and from phylloquinone-rich oils (including rapeseed, 74 
sunflower and olive oils).  Other forms of dietary vitamin K (menaquinones – vitamin 75 
K2) can be found but are more commonly produced by conversion from K1 in the 76 
intestine.  Vitamin K deficiency is common in groups at risk of cardiovascular disease, 77 
particularly those with end-stage CKD[2], possibly due to the overlap with dietary 78 
potassium restrictions. 79 
Vitamin K is essential for the activation of various proteins important in vascular and 80 
bone health.  These vitamin K dependent proteins (VKDP) include Matrix Gla protein 81 
(a potent inhibitor of vascular calcification), osteocalcin (a pro-osteoblastic hormone 82 
important in bone mineralization) and PIVKA-II (protein induced by vitamin K absence-83 
II, also known as des-gamma carboxyprothrombin, an abnormal form of prothrombin).  84 
These proteins contain Gla-domains which require activation (carboxylation) by 85 
gamma glutamyl carboxylase: a vitamin K-dependent process.  The uncarboxylated 86 
forms of these VKDP are used as biomarkers of vitamin K deficiency and are 87 
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detectable before manifestations of severe vitamin K deficiency (including bone 88 
fracture and uncontrolled bleeding) become clinically apparent.  It is known that high 89 
level of uncarboxylated VKDP (ucVKDP) is associated with surrogate markers of 90 
vascular health including VS and VC[3–6], but it is not clear whether ucVKDP are 91 
associated with hard endpoints, including cardiovascular events or mortality.   92 
Vitamin K supplementation may provide a straightforward and low-risk intervention 93 
which may reduce the development or progression of VC and VS, particularly in 94 
groups at high risk of cardiovascular disease prone to vitamin K deficiency.  The 95 
biological rationale is that vitamin K supplementation will saturate the gamma glutamyl 96 
carboxylase enzyme and maximise carboxylation (activation) of these VKDP.  The 97 
fully active VKDP are then able to exert their biological effects including the prevention 98 
or slowing of development of VC and VS.  Some trials of vitamin K supplementation 99 
have been conducted to assess effect on VC and VS, but have yielded inconsistent 100 
results[7–12].  We conducted a two-part systematic review and meta-analysis to 101 
explore our hypotheses that vitamin K supplementation improves markers of vascular 102 
disease and cardiovascular risk, specifically VC and VS, and that ucVKDP level is 103 
associated with incident cardiovascular disease and mortality. 104 
Methods 105 
Two investigators (JSL and FAC) independently searched Medline and 106 
Embase databases, Cochrane and ISRCTN registries from 1966 to 30/05/2017 using 107 
the following search terms for interventional studies relating to vitamin K (“vitamin K”, 108 
“menadiol”, “menadione”, “menaquinone”, “menatetrenone”, “phytonadione”, 109 
“methylphytyl”, “phylloquinone”, “phytomenadione”) and vascular health or ucVKDP 110 
(“cardiovascular”, “cardiac”, “coronary”, “vascular”, “vessel”, “artery”, “arterial”, “aorta”, 111 
“stiffness”, “distensibility”, “calcification”).  For longitudinal studies, we used terms 112 
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relating to ucVKDP (“dp-ucMGP”, “ucMGP”, “matrix Gla protein”, “osteocalcin”, 113 
“PIVKA”, “vitamin K deficiency”) and vascular disease (“cardiovascular”, “coronary”, 114 
“cardiac”, “CV”, “mortality”, “death”).  Both investigators reviewed titles and/or 115 
abstracts using Mendeley Desktop v1.17.12.  Reference lists of included articles and 116 
appropriate reviews[4,13–16] were screened for additional studies.  If eligibility was 117 
unclear, the full text article was obtained and screened against the inclusion/exclusion 118 
criteria and differences were resolved by discussion.  No language restrictions were 119 
applied though all eligible articles were written in English.  All relevant abstracts had 120 
subsequently been published as full reports.  Data were then extracted independently 121 
by two investigators (JSL and FAC).   122 
Clinical trials of Vitamin K supplementation 123 
This study is registered on PROSPERO (CRD42017060344).  PICOS 124 
(Population, Intervention, Comparison, Outcome, Setting) criteria for study inclusion 125 
are detailed in Supplemental Table S1.  We included randomised or non-randomised 126 
controlled trials conducted in adult human participants that compared vitamin K 127 
supplementation with control (placebo or no-treatment control group) for a period of 4 128 
weeks or more.  Studies with co-interventions in both arms were permitted, but vitamin 129 
K plus co-intervention versus placebo or control group was not.  Participants with any 130 
baseline level of VC or VS were considered eligible.  Studies using any form of vitamin 131 
K supplementation were considered, but only those supplementing K1 132 
(phytomenadione or phylloquinone) or K2 (menaquinone) were available (Table 1). 133 
We analysed the effect of vitamin K supplementation on VC, VS and ucVKDP 134 
(dp-ucMGP, ucOC; no relevant studies measured PIVKA-II).  We defined the following 135 
as appropriate measures to assess VC: plain lateral abdominal x-ray, computed 136 
tomography measuring coronary artery calcification or volume calcification scores].  137 
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The following were considered appropriate measures of VS: pulse wave velocity 138 
(carotid-femoral, carotid-radial or aortic using Doppler ultrasound or magnetic 139 
resonance imaging), compliance coefficient, distensibility coefficient or stiffness index.   140 
We extracted mean difference and standard deviation in VS, VC and ucVKDP 141 
from treatment and control groups.  Where mean change and standard deviation were 142 
not reported for outcome measures of interest[7,8,11,19], these were calculated using 143 
other available data. Specifically, the mean difference and standard deviation in VC 144 
were calculated from median, interquartile range and sample size[7] using a method 145 
described previously[20].  Standard deviation of VS or VKDP was calculated from 146 
mean and 95% confidence interval[8] or mean and P value[11,19] according to 147 
standard methods[21].  Percentage effect sizes in VC, VS and ucVKDP were 148 
calculated to account for heterogeneity of type and scale of outcome measures.  I2 149 
was assessed for each outcome measure as an estimation of consistency across 150 
studies.  Tau-squared, a point-estimate of the among-study variance, was expressed 151 
as a measure of true variance (heterogeneity) among included studies. Meta-152 
regression models were used to assess vitamin K form and dose, duration of follow-153 
up, year of publication and outcome score as potential sources of heterogeneity.  154 
Variables accounting for heterogeneity among studies were identified if their inclusion 155 
in the model resulted in a significant reduction in tau-squared. 156 
Study quality was assessed independently by two authors (JSL and FAC).  The 157 
Cochrane Risk of Bias tool[21] was used to assign a risk of bias score (Low, High or 158 
Unclear) for each of the following: random sequence generation, allocation 159 
concealment, blinding of participant and personnel, blinding of outcome assessment, 160 
incomplete outcome data, selective reporting and other bias.  Differences were 161 
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resolved by discussion.  We sought evidence of publication bias for all outcome 162 
measures using Trim and Fill analysis and Funnel plots.   163 
Meta-analyses were conducted according to a random effects model.  Analyses 164 
were conducted using meta and metafor packages for R statistical software (R Studio 165 
version 1.0.136).  166 
Vitamin K dependent proteins: longitudinal studies 167 
PICOS (Population, Intervention, Comparison, Outcome, Setting) criteria for 168 
study inclusion are detailed in Supplemental Table S1.  We included longitudinal adult 169 
human studies that assessed serum ucVKDP (desphopho-uncarboxyated Matrix Gla 170 
Protein (dp-ucMGP), uncarboxylated osteocalcin (ucOC) and PIVKA-II (protein 171 
induced by vitamin K absence-II)) at baseline and recorded incident cardiovascular 172 
events (fatal or non-fatal; myocardial infarction, other coronary heart disease, stroke) 173 
or mortality.   174 
Statistical analysis was conducted in two ways: i) using ucVKDP as a 175 
continuous variable: we extracted hazard ratios with 95% confidence intervals for risk 176 
of incident CVD (fatal or non-fatal) or all-cause mortality for increase in ucVKDP by 177 
one standard deviation, and ii) using ucVKDP in binary form, i.e. high versus low.  In 178 
studies reporting effect of baseline ucVKDP in quantiles of 3 or more, only the 179 
quantiles with the highest and lowest mean values of ucVKDP were included.  Specific 180 
cut-points used are detailed in Table 2.  We preferentially extracted hazard ratios 181 
adjusted for age and sex, or the closest approximation of this.  Hazard ratios and 95% 182 
confidence intervals were log transformed for analysis.  Regression analyses were 183 
used to assess factors associated with the study design or population that could 184 
account for heterogeneity in outcomes. 185 
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Results 186 
Clinical trials of Vitamin K supplementation 187 
We identified 5105 references, of which 11 studies were included in the meta-188 
analysis (Figure 1a); characteristics of included studies can be found in Table 1.  On 189 
random effects meta-analysis, there was a significant reduction in progression of VC 190 
with vitamin K supplementation versus control (3 studies, n=407; MD -9.14% [-17.8; -191 
0.52], p=0.038; Figure 2a).  There was a trend towards improvement in VS (3 studies, 192 
n=445; MD -3.70 [-7.77; 0.37]%, p=0.075; Figure 2b).  dp-ucMGP was significantly 193 
reduced with vitamin K supplementation (7 studies, n=872; MD -44.7 [-65.1; -24.3]%, 194 
p<0.0001; Figure 2c), as was ucOC (4 studies, n=962; MD -12.0 [-16.7; -7.2]%, 195 
p<0.0001; Figure 2d). 196 
Meta-regression showed no significant impact on VC or VS of vitamin K form 197 
or dose, year of publication, duration of follow-up or outcome score used on outcome 198 
score on univariate analysis [Supplementary Data: Table S2].  It was not possible to 199 
combine multiple variables for VC or VS analyses because of the small number of 200 
studies.  In studies assessing effect of vitamin K on dp-ucMGP, none of vitamin K form 201 
or dose, year of publication or duration of follow-up showed significant association with 202 
outcome on univariate analysis, however, in a combined model, longer duration of 203 
follow-up and higher vitamin K dose were significantly associated with outcome 204 
favouring vitamin K and accounted for 100% of heterogeneity in this case (Table 3 and 205 
Figure 3).  Earlier year of publication ( = 15.24, 95% CI 11.34-19.14, p<0.001) and 206 
longer duration of follow-up ( = -0.64, 95% CI -0.80 - -0.47, p<0.001) were 207 
significantly associated with reduction in ucOC in vitamin K groups, though the 4 208 
included studies were published over 2 consecutive years and this may not be 209 
clinically significant; year of publication was automatically dropped from the meta-210 
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regression models as a redundant variable due to perfect correlation with duration of 211 
follow-up (Table 4).   212 
Random sequence generation and allocation concealment were adequate in 213 
56% of studies, though 89% studies adequately blinded participants and personnel 214 
and 100% demonstrated blinding of outcome assessment (Supplementary Data: 215 
Table S3).  The effect of vitamin K supplementation on calcification and ucVKDP was 216 
maintained on assessment of publication bias using the Trim and Fill method 217 
(Supplementary Data: Figures S3 and S4) but was diminished for vascular stiffness 218 
(Supplementary Data: Figure S5). 219 
 220 
Vitamin K dependent proteins: longitudinal studies 221 
Of 1850 screened abstracts, we found 14 longitudinal studies (n=10,726) that 222 
recorded ucVKDP at baseline and recorded prospectively CVD events, mortality or 223 
both.  Twelve of 14 (85.7%) measured dp-ucMGP; 1 measured PIVKA-II and 1 224 
measured ucOC.  Study characteristics are detailed in Table 2; Figure 2b shows the 225 
flow chart of identified and excluded studies. 226 
There were 8 reported hazard ratios for step-wise increase in ucVKDP and 227 
association with CVD or mortality (n=5413), with median follow-up of 11.1 (IQR 8.6 – 228 
12.2) years.  Six of 8 of these studies reported an increased risk of CVD or mortality 229 
with increase in ucVKDP.  It was not possible combine these in a meta-analysis 230 
because of heterogeneity in reporting measures (see Supplementary Data: Table S4).    231 
In 7626 participants across 12 studies reporting ucVKDP as high versus low, 232 
median follow-up was 5.6 (IQR 3.0-10.0) years.  We combined only studies measuring 233 
dp-ucMGP (10 of 12) in a meta-analysis.  High dp-ucMGP was associated with 234 
combined endpoint of CVD/mortality (log HR 0.45 [0.07 - 0.83], p=0.02); however, 235 
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when CVD and mortality were considered separately, there was no significant 236 
association with either outcome (log HR 0.26 [-0.13 - 0.66], p=0.20; log HR 0.64 [-0.02 237 
- 1.29], p=0.06 Supplemental Figures 6a and 6b respectively).  In a subgroup of 238 
studies containing high-risk groups (CKD, vascular disease or diabetes), high dp-239 
ucMGP level was associated with mortality (log HR 0.87 [0.13 – 1.62], p=0.02).  This 240 
effect was not maintained when assessed in 3 studies[6,22,23] with CKD only (log HR 241 
0.11 [-0.44 – 0.67], p=0.69). 242 
There was no association of PIVKA-II (HR 1.71 (0.79-3.7), p=0.173)[24] or ucOC 243 
(HR 1.13 (0.85 – 1.5))[25] with CVD events in two other studies. 244 
Funnel plots and Trim and Fill analysis suggest publication bias in favour of positive 245 
results for those studies reporting ucVKDP as high versus low (Supplementary Data: 246 
Figure S7). 247 
All studies were longitudinal cohort studies in design measuring baseline ucVKDP 248 
and assessing for incident CVD, mortality or both.  The average duration of follow-up 249 
ranged from 1.9 – 14.1 years.  The definition of high ucVKDP differed across studies.  250 
In 12 of 14 studies measuring dp-ucMGP at baseline, the cut-point for high dp-ucMGP 251 
varied from >400 to >1977 pmol/l depending on the population (Table 2), which may 252 
have confounded the results.  Multiple regression analysis did not detect any 253 
significant association between reported hazard ratio of CVD or mortality and duration 254 
of follow-up (p=0.234), cut point used for dp-ucMGP (p=0.649) or high-risk versus 255 
standard-risk groups (p=0.815). 256 
Discussion 257 
Vitamin K supplementation significantly reduces ucVKDP in serum and 258 
improves VC with a trend towards improving VS in limited studies.  We have shown 259 
that ucVKDP are not associated with CVD but may be associated with mortality or a 260 
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combined endpoint of CVD/mortality.  Our results are in keeping with a recent review 261 
of the association between vitamin K status and cardiovascular health, which reported 262 
inconsistent association of dp-ucMGP concentrations with cardiovascular or all-cause 263 
mortality[26].  It is impossible to exclude other confounding variables contributing to 264 
both vitamin K deficiency and risk of mortality, such as malnutrition.  Despite apparent 265 
sensitivity in detecting changes in vitamin K status, ucVKDP in this form are unlikely 266 
to be informative biomarkers in predicting vascular risk.   267 
VC is associated with VS, and both are associated with mortality[27–29].  There 268 
has been increasing interest in the potential therapeutic ability of vitamin K to reduce 269 
progression of VC.  There are only 3 completed studies available for analysis, and 270 
only one was placebo-controlled; the other 2 included co-interventions containing 271 
vitamin D. There is increasing evidence for a synergistic effect between vitamins D 272 
and K[30]: vitamin D is thought to influence production of ucVKDP.  It is difficult to 273 
comment on the effect of vitamin K alone in the setting of co-administration with 274 
another biologically active compound, however, vitamin K+D groups showed greater 275 
changes in VC and VS than groups receiving co-interventions (including vitamin D) 276 
alone.  The combined existing data are favourable in suggesting improved vascular 277 
health in a variety of patient populations treated with vitamin K compared with control.  278 
Given the limited data and weaknesses of the analysis described below, these results 279 
must be interpreted with caution, but we believe they support the case for conducting 280 
clinical trials in other population and disease groups to assess efficacy of vitamin K 281 
supplementation on cardiovascular heatlh.  To date, we have identified 7 ongoing or 282 
unreported clinical trials of the effect of oral vitamin K1 or K2 supplementation on VS 283 
or VC (Supplementary Data: Table S5).  Pending the outcome of these ongoing 284 
studies, larger Phase 3 trials may be warranted. 285 
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 The weaknesses of the analysis of clinical trials lie in the heterogeneous nature 286 
of the studies, both in vitamin K formulation and dose and variability in the means used 287 
to assess VS and VC.  Population-level analyses (in Europe and the USA) suggests 288 
“adequate” intakes of vitamin K are sub-optimal; all studies using vitamin K1 289 
supplementation appear to have given doses greater than the dietary 290 
recommendations for adequate vitamin K1 (phylloquinone) intake of around 1 291 
microgram/kg phylloquinone per day[31].  There is no available advice on 292 
recommended intake of K2, though K2 is considered a more potent form than is 293 
K1[32], and thus larger doses of K1 than K2 are likely to be required.  The clinical trials 294 
were relatively small with variable duration and there was unknown risk of reporting 295 
bias.  Our meta-regression models suggest longer duration of follow-up and possibly 296 
higher vitamin K dose is associated with a greater reduction in ucVKDP, but we were 297 
unable to confirm these associations with vascular calcification or stiffness.  There was 298 
significant heterogeneity in the longitudinal studies in terms of the populations 299 
assessed, ucVKDP measured, cut-points used to define high ucVKDP, and the 300 
duration of follow-up.  In both clinical trials and longitudinal analyses, the published 301 
studies report outcomes across a variety of populations, including healthy groups; it is 302 
difficult to know the ‘at risk’ populations.   303 
This study was conducted and reported in accordance with recognised 304 
guidelines[33,34].  The longitudinal data are difficult to summarise because they are 305 
conducted in different populations with variable end-point definitions, though the data 306 
are abundant and clinically plausible, and therefore likely to be correct.  307 
We have shown that vitamin K supplementation does reduce absolute level of 308 
ucVKDP.  We were surprised to find a lack of association of ucVKDP, predominantly 309 
as dp-ucMGP, with cardiovascular morbidity or mortality.  If we are to assume that 310 
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vitamin K is as important for vascular health as the published data suggest, there are 311 
a few possible explanations.  First, we have reported only on association of absolute 312 
level of ucVKDP and their association with CVD or mortality.  In a cohort of patients 313 
with advanced CKD requiring dialysis, patients with calcific uraemic arteriolopathy 314 
(CUA) had similar total levels of uncarboxylated MGP and carboxylated MGP, but a 315 
lower proportion of carboxylated:total MGP compared with controls matched for age, 316 
sex, race and use of warfarin[35].  The risk of CUA markedly increased with reduction 317 
in concentration of carboxylated MGP.  Ratio of carboxylated:uncarboxylated MGP 318 
may be a more clinically informative biomarker.  Second, serum dp-ucMGP has no 319 
known biological effect, but is thought to be associated with of level of available MGP 320 
in the vessel wall[36].  There are no commercially available assays to measure protein 321 
level or activity in the vessel wall itself; serum levels of MGP species may not 322 
associated with biological effect. Finally, in high-risk populations such as patients with 323 
CKD and/or diabetes, it is possible that death related to extensive vascular disease 324 
such as sepsis from an ischaemic limb may not actually be classified as cardiovascular 325 
death. 326 
In 2941 participants in the Framingham Heart Study, high intake of vitamin K 327 
such as from green vegetables was associated with significantly higher intake of fruits, 328 
fish, fibre and dietary supplements, and significantly lower intake of red meat and 329 
saturated fat[37].  Those adopting a heart-healthy diet may also be more likely to 330 
undertake regular exercise.  The observed effects of vitamin K status on 331 
cardiovascular morbidity or mortality may therefore serve as a more complex marker 332 
of healthy diet and lifestyle. Similarly, supplementation of vitamin K cannot replace the 333 
other benefits obtained by eating a health-balanced diet and undertaking regular 334 
exercise.  Nevertheless, interest in vitamin K as a therapeutic option has been greatest 335 
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in populations at high risk of CVD, in whom vitamin K deficiency is prevalent and can 336 
be treated more readily with vitamin K supplementation than with lifestyle overhaul.  337 
When a satisfactory biomarker becomes routinely available, there may be an 338 
argument for testing vitamin K status in high-risk groups and supplementing 339 
accordingly.  However, before this translates to clinical practice, the following steps 340 
are required. First, confirmation of the most clinically appropriate biomarker to 341 
measure vitamin K deficiency and specify the cut-point. Second, further trials of 342 
vitamin K on surrogate markers of vascular health and required to identify the optimum 343 
dose, preparation and duration of treatment. Finally, larger Phase 3 trials are 344 
necessary to establish the effect of vitamin K on hard endpoints including CVD and 345 
mortality. 346 
In conclusion, this analysis provides some evidence of benefit of vitamin K 347 
supplementation on surrogate markers of vascular health.  Further trials (both on 348 
surrogate markers of VS and VC, and large, cardiovascular outcome trials) are needed 349 
before supplementation can be recommended.  Low dietary vitamin K intake is likely 350 
to be important particularly in higher risk groups such as older populations, and those 351 
with diabetes, vascular disease and CKD.  Vitamin K supplementation may prove to 352 
be of benefit as a long-term strategy to improve vascular health and reduce 353 
cardiovascular risk.  354 
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Table 1 
Population 
risk 
Author Yr Country N= Population VK 
form 
Dose 
(mcg/day) 
Control Durn Outcome 
measure 
High Shea[7] 2009 USA 295 Older adults K1 500 Multivitamin 
(including D) 
36 Coronary artery 
calcification score 
Shea[38] 2011 USA 374 Older adults K1 500 No treatment 36 dp-ucMGP 
(pmol/l) 
Kurnatowska[11] 2015 Poland 40 CKD K2-MK7 90 Vitamin D 9 Coronary artery 
calcification score; 
dp-ucMGP 
(pmol/l) 
Fulton[8] 2016 Scotland 80 Older adults, vascular 
disease 
K2-MK7 100 Placebo 6 Pulse wave 
velocity 
(SphygmoCor); 
dp-ucMGP 
(pmol/l) 
Brandenburg[12] 2017 Germany 72 Aortic stenosis or 
sclerosis 
K1 2000 Placebo 12 Aortic valve 
calcification score; 
dp-ucMGP 
(pmol/l) 
Standard Braam[9] 2004 Netherlands 121 Healthy K1 1000 Multivitamin 
(including D) 
36 Compliance 
coefficient 
(mm2/kPa) 
Booth[39] 2008 USA 452 Healthy men and 
postmenopausal 
women 
K1 500 Multivitamin and 
calcium /vitamin D 
36 ucOC (%) 
Binkley[40] 2009 USA 381 Postmenopausal 
women 
K1 & 
K2-MK4 
1000 K1 
15000 K2 
Calcium /vitamin D 12 ucOC (%) 
Dalmeijer[19] 2012 Netherlands 38 Healthy K2-MK7 360 Placebo 3 dp-ucMGP 
(pmol/l) 
Theuwissen[41] 2012 Netherlands 24 Healthy K2-MK7 360 Placebo 3 dp-ucMGP 
(pmol/l) 
Knapen[10] 2015 Netherlands 244 Postmenopausal 
women 
K2-MK7 180 Placebo 36 Pulse wave 
velocity 
(SphygmoCor); 
dp-ucMGP 
(pmol/l) 
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Characteristics of clinical trials which compared vitamin K supplementation versus control on vascular calcification, vascular stiffness 
or serum level of vitamin K dependent protein.  Population risk was considered high if conducted in the following populations: older 
patients (> 60 years), diabetes, pre-existing vascular disease or chronic kidney disease/dialysis/renal transplantation.  Yr: year study 
published; VK form: form of vitamin K used in study; Durn: duration of study in months. 
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Table 2 
 
 
Population 
risk 
Author Year Country N= Population FU 
(yrs) 
VKDP 
measured 
Change in VKDP for which 
HR given 
Outcome 
High Schurgers[6] 2010 France 107 Chronic kidney disease 2.3 dp-ucMGP Per 100pm log-transformed 
increase; >921 vs. <921 pmol/l 
Mortality 
Ueland[42] 2010 Norway 118 Symptomatic aortic 
stenosis 
1.9 dp-ucMGP >950 vs. <950 pmol/l Mortality 
Schlieper[23] 2011 Serbia 188 Haemodialysis versus 
normal renal function 
3 dp-ucMGP Higher than median versus 
lower (median value not 
reported) 
CVD; mortality 
Ueland[43] 2011 Norway 179 Stable heart failure 2.9 dp-ucMGP >1977 vs. <1977 pmol/l Mortality 
Dalmeijer[44] 2013 Netherlands 518 Type 2 diabetes 11.2 dp-ucMGP Per one SD increase CVD 
van den 
Heuvel[45] 
2014 Netherlands 192 Older adults (LASA) 5.6 dp-ucMGP Per 100pm log-transformed 
increase; highest versus lowest 
tertile (>400 vs <266 pmol/l) 
CVD 
Mayer[46] 2014 Czech 
Republic 
799 Coronary heart disease or 
ischaemic stroke 
5.6 dp-ucMGP >977  vs. <977 pmol/l CVD; mortality 
Keyzer[22] 2015 Netherlands 518 Renal transplant 9.6 dp-ucMGP Per unit increase (log-
transformed); highest vs. 
lowest quartiles (>1535 vs. 
<734 pmol/l) 
Mortality 
Yeap[25] 2015 Australia 3389 Older men (70-89 years) 7 ucOC >28.2  vs. <28.2 microgram/l CVD 
Mayer[47] 2016 Czech 
Republic 
799 Stable vascular disease 5.6 dp-ucMGP >977  vs. <977 pmol/l Mortality 
Shea[48] 2017 USA 635 Older men and woman 
(Health ABC) 
12.1 dp-ucMGP >574 vs. <574pmol/l CVD 
Standard Dalmeijer[49] 2014 Netherlands 1406 Women undergoing breast 
cancer screening (EPIC-
NL) 
11.5 dp-ucMGP Per one SD increase; highest 
vs. lowest quartiles (mean 348 
vs. 47 pmol/l) 
CVD 
Liu[50] 2015 Belgium 789 FLEMENGHO: no CVD at 
baseline 
14.1 dp-ucMGP Per unit increase of squared 
dp-ucMGP 
CVD; mortality 
Danziger[24] 2016 USA 355 MESA 11 PIVKA-II > 4.64 vs. <2.4 ng/ml CVD 
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Characteristics of longitudinal studies measuring vitamin K dependent protein at baseline and recording incident cardiovascular 
disease/mortality.  Population risk considered high if conducted in the following populations: older patients (>60 years), diabetes, pre-
existing vascular disease or chronic kidney disease/dialysis/renal transplantation.  dp-ucMGP: desphospho-uncarboxylated Matrix 
Gla protein.  PIVKA-II: Protein induced by vitamin K absence - II.  MESA: Multi-Ethnic Study of Atherosclerosis.  Heart and Soul 
Study:  history of ischaemic heart disease.  EPIC-NL: Dutch contribution to European Prospective Investigation into Cancer and 
Nutrition cohort.  FLEMENGHO: Flemish Study on Genes, Environment, and Health Outcomes (1985-2004).  Health ABC: 
Prospective longitudinal cohort study to examine age-related changes in physical function and body composition in older black and 
white men and women.  LASA: Longitudinal Aging Study Amsterdam.  Health In Men Study:  cohort study of community-dwelling 
older men from Perth, Western Australia. 
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Table 3 
Meta-regression model with the mean difference (%) in dp-ucMGP as the dependent variable 
 
 
 
  
Variable Unadjusted 
 Coefficient 95% CI P Tau2 
No covariate  451.1 
Year of publication 6.39 -1.24, 14.02 0.10 232.7 
Duration of follow-up -0.82 -1.86, 0.22 0.12 185.3 
Vitamin K form 23.64 -13.33, 60.60 0.21 278.0 
Dose -0.01 -0.04, 0.02 0.42 366.1 
 Adjusted 
Model 1     
Duration of follow-up -0.82 -1.58, -0.05 0.04 66.7 
Vitamin K form 19.72 -6.97, 46.42 0.15  
Model 2     
Duration of follow-up -1.03 -1.45, -0.61 <0.001 0.0 
Dose -0.02 -0.04, 0.00 0.045  
Model 3     
Duration of follow-up -0.51 -1.67,0.65 0.39 195.1 
Year of publication 5.01 -2.99, 13.00 0.22  
Model 4     
Duration of follow-up -0.70 -2.23, 0.83 0.37 339.5 
Dose -0.01 -0.06, 0.04 0.68  
Vitamin K form 6.74 -62.58, 76.05 0.85  
Model 5     
Duration of follow-up -0.81 -1.31, -0.31 0.002 0.74 
Dose -0.02 -0.04, -0.001 0.04  
Year of publication 4.60 -0.93, 10.13 0.10  
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Table 4 
Meta-regression model with the mean difference (%) in ucOC as the dependent variable 
*Redundant variable (year of publication) was dropped from Models 1, 4 and 5 due to perfect correlation with duration of follow-up.  
 
  
Variable Unadjusted 
 Coefficient 95% CI P Tau2 
No covariate  20.3 
Year of publication 15.24 11.34-19.14 <0.001 0.00 
Duration of follow-up -0.64 -0.80, -0.47 <0.001 0.00 
Vitamin K form 9.93 -9.86, 29.72 0.33 74.9 
Dose 0.001 -0.001, 0.002 0.29 71.5 
 Adjusted 
Model 1*     
Year of publication Redundant – dropped from model 0.00 
Duration of follow-up -0.64 -0.80, -0.47 <0.001 0.00 
Model 2     
Year of publication 15.08 11.07, 19.08 <0.001 0.00 
Dose 0.00 0.00, 0.00 0.73  
Model 3     
Duration of follow-up -0.63 -0.80, -0.46 <0.001 0.00 
Dose 0.00 0.00, 0.00 0.73  
Model 4*     
Year of publication Redundant – dropped from model  
Duration of follow-up -0.63 -0.80, -0.46 <0.001 0.00 
Dose 0.00 0.00, 0.00 0.73  
Model 5*     
Year of publication Redundant – dropped from model  
Duration of follow-up -0.63 -0.80, -0.46 <0.001 0.00 
Vitamin K form 0.32 -1.48, 2.12 0.73  
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Legends 
Figure 1  
Flow chart of included (A) clinical trials and (B) longitudinal studies 
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Figure 2 
Forest plots showing the effect of vitamin K supplementation on % change in vascular calcification (A), vascular stiffness (B), dp-
ucMGP (C) and ucOC (D).  Random effects meta-analysis was used. Data are presented as mean % difference and 95% confidence 
interval. 
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Figure 3 
Meta-regression plot of mean difference (%) and (A) duration of follow-up ( = -0.82, 95% CI -1.86 - 0.22, p=0.12) and (B) vitamin K 
dose ( = -0.01, 95% CI -0.04 - 0.02, p=0.42).  Negative values favour intervention and positive values favour control.  Circles 
represent studies included in the meta-analysis.  The size of the circle is inversely proportional to the variance of the estimated 
treatment effect.  The solid line indicates a perfect fit.    
 
